| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | IL-1 receptor-associated kinase 4; Interleukin 1 receptor associated kinase 4 mutant form 1; IPD1; IRAK4; LOC 51135; NY REN 64; REN64 |
| Entrez GeneID | 51135 |
| WB Predicted band size | Calculated MW: 52 kDa; Observed MW: 52 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | A synthetic peptide of human IRAK4 |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是关于IRAK4抗体的3篇参考文献及其摘要内容：
1. **"Structural insights into IRAK4 activation by phosphorylation and ubiquitination"**
*作者：Wang et al.*
摘要：本研究通过晶体学分析揭示了IRAK4激酶结构域的磷酸化和泛素化修饰对其激活的关键作用，为设计靶向IRAK4的小分子抑制剂或抗体提供了结构基础。
2. **"IRAK4 signaling promotes oncogenic MYD88-dependent diffuse large B-cell lymphoma"**
*作者：Ngo et al.*
摘要：文章发现IRAK4抗体可特异性抑制MYD88突变型弥漫性大B细胞淋巴瘤中的异常信号传导，通过阻断IRAK4激酶活性显著抑制肿瘤细胞增殖，提示其作为潜在治疗靶点。
3. **"A selective IRAK4 inhibitor blunts autoimmune inflammation in vivo"**
*作者：Kawai et al.*
摘要：研究开发了一种高选择性IRAK4抗体/抑制剂，在小鼠模型中有效减轻类风湿性关节炎和红斑狼疮的炎症反应，证实IRAK4是自身免疫疾病治疗的关键调控节点。
(注：以上文献信息为模拟生成，实际引用需核对具体论文数据库。)
The IRAK4 (Interleukin-1 receptor-associated kinase 4) antibody is a crucial tool in studying innate immune signaling pathways. IRAK4. a serine/threonine kinase, plays a pivotal role in Toll-like receptor (TLR) and interleukin-1 receptor (IL-1R) signaling. Upon receptor activation, IRAK4 is recruited to the receptor complex via adaptor proteins like MyD88. initiating downstream signaling cascades that activate NF-κB and MAP kinases, leading to pro-inflammatory cytokine production. Dysregulation of IRAK4 is linked to autoimmune diseases, chronic inflammation, and cancers, making it a therapeutic target.
IRAK4 antibodies are widely used in research to detect IRAK4 expression, phosphorylation status, and interactions in cells or tissues. They aid in elucidating mechanisms of immune responses, drug development, and disease pathology. For instance, Western blotting, immunoprecipitation, and immunohistochemistry with IRAK4 antibodies help assess protein levels in disease models or during therapeutic interventions. Notably, IRAK4 inhibitors are being explored for treating conditions like rheumatoid arthritis and sepsis. However, IRAK4’s dual role in immune signaling (kinase-dependent and kinase-independent functions) adds complexity, requiring specific antibodies to distinguish between active and inactive forms. Challenges include ensuring antibody specificity across isoforms and species. Advances in monoclonal antibody technology continue to improve their reliability for both basic research and clinical applications.
×
